Ladenburg Thalmann Starts Aviragen Therapeutics (AVIR) at Buy
- Wall Street drops as banks, health stocks weigh
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Morgan Stanley (MS) Tops Q4 EPS by 17c
- Trump, Brexit uncertainty hit stocks and dollar, gold jumps
- Pre-Open Stock Movers 01/17: (FWP) (CLSN) (GEVO) Higher; (ADHD) (CBK) (UEC) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Ladenburg Thalmann initiated coverage on Aviragen Therapeutics (NASDAQ: AVIR) with a Buy rating and a price target of $2.50.
Shares of Aviragen Therapeutics closed at $1.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Starts Kratos Defense & Security (KTOS) at Buy
- UPDATE: JPMorgan Downgrades OneMain (OMF) to Neutral
- UPDATE: JPMorgan Upgrades American Express (AXP) to Overweight
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesLadenburg Thalmann Financial Services
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!